Changeflow GovPing Healthcare & Life Sciences Biotic Superparamagnetic Nanoparticles from Col...
Routine Rule Added Final

Biotic Superparamagnetic Nanoparticles from Colchicum ritchii

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO published Application US20260108580A1 on April 23, 2026, covering a method for preparing biotic superparamagnetic nanoparticles using Colchicum ritchii plant extract combined with ferric chloride and sodium hydroxide solutions. The application, filed on January 17, 2025 under Application No. 19028200, names three inventors: Veeramani Chinnadurai, Khalid A. Al-Numair, and Mohammed A. Alsaif. CPC classifications indicate pharmaceutical applications targeting metabolic disorders including obesity (A61P 3/04) and diabetes (A61P 3/10).

“A method of preparing biotic super-paramagnetic nanoparticles can include combining a Colchicum ritchii plant extract with a ferric chloride solution to provide a mixture and adding sodium hydroxide solution to the mixture to provide the super-paramagnetic nanoparticles.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.

What changed

The USPTO published Application US20260108580A1 disclosing a method for synthesizing biotic superparamagnetic nanoparticles by combining Colchicum ritchii plant extract with ferric chloride solution and adding sodium hydroxide to precipitate the nanoparticles. The invention is classified under multiple A61K subclasses including A61K 36/88 (plant extracts), A61K 9/5115 and A61K 9/5192 (nanoparticle formulations), A61K 47/02 (inorganic compounds), and therapeutic classes A61P 3/04 (anti-obesity) and A61P 3/10 (anti-diabetic).

Manufacturers and researchers in the pharmaceutical and biotechnology sectors developing nanoparticle-based drug delivery systems may find this patent relevant, particularly for metabolic disorder applications. The Colchicum ritchii-derived nanoparticle platform represents a plant-based synthesis route for magnetic nanoparticles with potential therapeutic uses, warranting review by parties working in obesity or diabetes drug formulation.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METHOD FOR PREPARING BIOTIC SUPERPARAMAGNETIC NANOPARTICLES DERIVED FROM COLCHICUM RITCHII

Application US20260108580A1 Kind: A1 Apr 23, 2026

Inventors

VEERAMANI CHINNADURAI, KHALID A. AL-NUMAIR, MOHAMMED A. ALSAIF

Abstract

A method of preparing biotic super-paramagnetic nanoparticles can include combining a Colchicum ritchii plant extract with a ferric chloride solution to provide a mixture and adding sodium hydroxide solution to the mixture to provide the super-paramagnetic nanoparticles.

CPC Classifications

A61K 36/88 A61K 9/5115 A61K 9/5192 A61K 47/02 A61P 3/04 A61P 3/10

Filing Date

2025-01-17

Application No.

19028200

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260108580A1

Who this affects

Applies to
Manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application IP licensing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!